Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, developm ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces positive topline results from a U.S. Phase II, 24-week study for its subcutaneous (SQ) depot formulations of small molecule GLP-1 receptor ...

ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after ...

Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab ...

Risankizumab showed high rates of clinical remission and endoscopic response when administered as subcutaneous induction therapy for moderate to severe CD.

The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

One experimental injection helped mice and pigs heal after heart attack by boosting a protective heart hormone. (CREDIT: ...

Roche and Zealand Pharma's obesity drug petrelintide showed up to 11% weight loss in a Phase 2 trial with strong safety results.

Weight loss drugs have been linked to lowering the risk of many serious conditions, including dementia. Now, experts are ...

No. 3 / 2026Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo ...